Baseline patient demographics
| Characteristic . | Patients (n = 21) . |
|---|---|
| Median age, y (range) | 59.0 (29-74) |
| Male, n (%) | 16 (76) |
| Baseline SWOG stage of MM, n (%) | |
| 1 | 7 (33) |
| 2 | 8 (38) |
| 3 | 5 (24) |
| 4 | 1 (5) |
| Baseline ECOG performance status, n (%) | |
| 0 | 14 (67) |
| 1 | 5 (24) |
| 2 | 2 (10) |
| Prior therapies, n (%) | 21 (100) |
| Stem cell transplantation | 15 (71) |
| Autologous transplantation | 13 (62) |
| Allogenic transplantation | 2 (10) |
| Systemic therapy | 21 (100) |
| Dexamethasone | 19 (90) |
| Cyclophosphamide | 16 (76) |
| Melphalan | 15 (71) |
| Vincristine | 14 (67) |
| Thalidomide | 13 (62) |
| Doxorubicin | 11 (52) |
| Prednisolone | 8 (38) |
| Bortezomib | 6 (29) |
| Doxorubicin hydrochloride | 6 (29) |
| Carmustine | 3 (14) |
| Interferon | 3 (14) |
| Characteristic . | Patients (n = 21) . |
|---|---|
| Median age, y (range) | 59.0 (29-74) |
| Male, n (%) | 16 (76) |
| Baseline SWOG stage of MM, n (%) | |
| 1 | 7 (33) |
| 2 | 8 (38) |
| 3 | 5 (24) |
| 4 | 1 (5) |
| Baseline ECOG performance status, n (%) | |
| 0 | 14 (67) |
| 1 | 5 (24) |
| 2 | 2 (10) |
| Prior therapies, n (%) | 21 (100) |
| Stem cell transplantation | 15 (71) |
| Autologous transplantation | 13 (62) |
| Allogenic transplantation | 2 (10) |
| Systemic therapy | 21 (100) |
| Dexamethasone | 19 (90) |
| Cyclophosphamide | 16 (76) |
| Melphalan | 15 (71) |
| Vincristine | 14 (67) |
| Thalidomide | 13 (62) |
| Doxorubicin | 11 (52) |
| Prednisolone | 8 (38) |
| Bortezomib | 6 (29) |
| Doxorubicin hydrochloride | 6 (29) |
| Carmustine | 3 (14) |
| Interferon | 3 (14) |
SWOG indicates Southwest Oncology Group; MM, multiple myeloma; and ECOG, Eastern Cooperative Oncology Group.